Exelixis, Inc.

Tae-Gon Baik

Chris Allen Buhr

Sunghoon Ma

Longcheng Wang

John M Nuss

Bryan K S Yeung

Katherine Lara

Neel Kumar Anand

Tsze Tsang

Csaba J Peto

Kenneth D Rice

Abigail R Kennedy

Larisa Dubenko

Zerom Tesfai

Yong Wang

Timothy Patrick Forsyth

James William Leahy

David J Matthews

Naing N Aay

Joerg Bussenius

Larry Wayne Mann

Jeff Z Chen

Morrison B Mac

Charles M Blazey

Grace Mann

Simona Costanzo

Tai Phat Huynh

Peter Lamb

Jean-Claire Limun Manalo

Angie Inyoung Kim

Craig Stacy Takeuchi

Erick Wang Co

Owen Joseph Bowles

Jeffry Kimo Curtis

Lisa Esther Dalrymple

Sergey Epshteyn

Steven Charles Defina

Xian Shi

Mohamed Ibrahim

Arlyn Arcalas

Kevin Luke Schnepp

Baili Chen

Jeff Chen

Nicole Miller

Jeffrey Kimo Curtis

Bryan K Yeung

Tsze H Tsang

Bryan K S Novartis Institute For Tropical Diseases Yeung

Thimothy Patrick Forsyth

Mohamed Abdulkader Ibrahim

Lary Wayne Mann

Bryan KS Novartis Institute For Tropical Diseases Yeung

The present invention provides compounds for modulating protein kinase enzymatic activity for modulating cellular activities such as proliferation, differentiation, programmed cell death, migration and chemoinvasion. Compounds of the invention inhibit, regulate and/or modulate kinases. Methods of using the compounds and pharmaceutical compositions thereof to treat kinase-dependent diseases and conditions are also an aspect of the invention.

Pyrazole kinase modulators and methods of use

The invention is directed to Compounds of Formula I and pharmaceutically acceptable salts or solvates thereof, as well as methods of making and using the compounds. 

Pyridopyrimidinone inhibitors of PI3K&#x3b1; for the treatment of cancer

The invention is directed to Compounds of Formula I: optionally as a single stereoisomer or mixture of stereoisomers thereof, and additionally optionally as a pharmaceutically acceptable salt thereof; as well as methods of making and using the compounds.

Pyridopyrimidinone inhibitors of PI3K&#x3b1; and mTOR

The invention is directed to Compounds of Formula I: and pharmaceutically acceptable salts or solvates thereof, as well as methods of making and using the compounds.

Substituted pyrido[2,3-d]pyrimidin-7(8H)-one inhibitors of phospatidylinositol 3-kinase alpha

A compound according to Formula I or II: wherein R, R, R, L, and Land Lare as defined in the specification, pharmaceutical compositions thereof, and methods of use thereof.

Tropane compounds

This invention relates to compounds for modulating protein kinase enzymatic activity for modulating cellular activities such as proliferation, differentiation, programmed cell death, migration and chemoinvasion, and to pharmaceutical compositions containing such compounds. Even more specifically, the invention relates to compounds that inhibit, regulate and/or modulate kinases, particularly Checkpoint Kinases, even more particularly Checkpoint Kinase 1, or Chk1. Methods of therapeutically or prophylactically using the compounds and compositions to treat kinase-dependent diseases and conditions are also an aspect of the invention, and include methods of treating cancer, as well as other disease states associated with unwanted angiogenesis and/or cellular proliferation, by administering effective amounts of such compounds.

Protein kinase modulators and methods of use

Growing community of inventors

Foster City, CA, United States of America

Tae-Gon Baik